Cumberland Pharmaceuticals

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Cumberland Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#415 of 15,742 sponsors by registered trial count).

43 total trials 1 currently recruiting 37 completed top decile by trial count

Cumberland Pharmaceuticals: 43 sponsored US clinical trials, 1 recruiting.

Cumberland Pharmaceuticals sponsors 43 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 37 completed. 23 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hyponatremia, with 3 trials.

Top-decile sponsor footprint

Cumberland Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#415 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

37 of 41 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

43 total, page 1 of 1

RECRUITING Phase 2

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT05571059

ACTIVE NOT RECRUITING Phase 2

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT02682511

COMPLETED Phase 2

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675

COMPLETED Phase 2

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

NCT03611010

COMPLETED Phase 4

Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients

NCT02583399

COMPLETED Phase 2

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

NCT03028350

COMPLETED Phase 2

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

NCT02802228

TERMINATED Phase 1

Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)

NCT02013141

TERMINATED Phase 3

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

NCT02208063

COMPLETED

Telavancin Observational Use Registry (TOUR)

NCT02288234

COMPLETED Phase 2

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

NCT02216357

COMPLETED Phase 2

Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy

NCT02123017

COMPLETED Phase 2

2 Regimens of Lactulose for Colonoscopy Preparation in Adults

NCT01887470

COMPLETED Phase 4

Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery

NCT01901393

COMPLETED Phase 4

A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery

NCT01650519

TERMINATED Phase 3

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT01451411

COMPLETED Phase 2

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

NCT01436500

COMPLETED Phase 3

Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy

NCT01332253

COMPLETED Phase 4

Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

NCT01334944

COMPLETED Phase 4

Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

NCT01334957

COMPLETED Phase 1

A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

NCT01370148

COMPLETED Phase 1

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

NCT01238796

TERMINATED Phase 3

Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection

NCT01118663

COMPLETED Phase 3

Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients

NCT01002573

COMPLETED Phase 4

A Preference Study Comparing Kristalose® and Liquid Lactulose

NCT00712543

COMPLETED Phase 1

Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

NCT00887627

COMPLETED Phase 1

Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

NCT00851227

COMPLETED Phase 3

Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients

NCT00606489

COMPLETED Phase 3

Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients

NCT00470600

COMPLETED Phase 3

Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT00478192

COMPLETED Phase 4

A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT00435591

COMPLETED Phase 3

A Study of Caldolor in Hospitalized Febrile Pediatric Patients

NCT00225706

COMPLETED Phase 3

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00107978

COMPLETED Phase 3

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

NCT00107952

COMPLETED Phase 3

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819

COMPLETED Phase 3

Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients

NCT00225732

COMPLETED Phase 3

An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

NCT00379847

COMPLETED Phase 2

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00077675

COMPLETED Phase 2

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

NCT00062647

COMPLETED Phase 2

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00061633

COMPLETED Phase 2

Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

NCT00057356

COMPLETED Phase 3

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

NCT01131000

COMPLETED Phase 3

Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

NCT00380575

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 14
Phase 3 16
Phase 4 7

What is open in the Cumberland Pharmaceuticals pipeline

1 recruiting of 43 indexed (2% open); 37 completed (86%).

Phase mix: 23 late (III/IV) vs 19 early (I/II) (balanced across stages).

Top condition: Hyponatremia (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Cumberland Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 43 registered trials and 2% open enrollment, not the therapeutic-area sidebar.

Cumberland Pharmaceuticals sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150 0%5%10%15%20%25% Total trials Recruiting share Cumberland PharmaceuticalsAtlantic Health SystemLahey ClinicOctapharmaSeattle Institute for Biomedical and Clinical ResearchNSABP FoundationTriHealthBaxter Healthcare CorporationCenters for Disease Control and Prevention
Cumberland Pharmaceuticals sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cumberland Pharmaceuticals sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 43 trials (± recruiting share)

Sponsors near 2% open enrollment (± trial volume)

What to do with this Cumberland Pharmaceuticals page

43 registered trials is a research-attention snapshot, not an endorsement of Cumberland Pharmaceuticals or any single study.

  • 1 of Cumberland Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hyponatremia is the condition Cumberland Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hyponatremia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cumberland Pharmaceuticals pipeline card: 43 registered trials from official public datasets.Report a data error.